• Home
  • Study Details
COM_RESEARCHSTUDIES_DETAIL_AVAL_STATUS_4

A Study of Investigational Medication for Relapsed or Refractory Multiple Myeloma

In this study, we want to compare different combinations of drugs for patients with multiple myeloma who have not responded to previous treatment. We want to learn if an investigational medication may be beneficial for the treatment of multiple myeloma.

Age & Gender

  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive

Contact the Team

Location

COM_RESEARCHSTUDIES_DETAIL_HEADER_BASIC_CONTACT_4

North Carolina (Statewide)

Additional Study Information

Principal Investigator

Samuel Rubinstein
LCCC - Clinical Trials

Study Type

Clinical or Medical
Interventional

Study Topics

Blood Conditions
Cancer (Multiple Myeloma)

IRB Number

22-2031

ClinicalTrials.gov

NCT05455320

Research for Me logo

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.
logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research